Purpose of Review We discuss current research on the mental health effects of COVID-19 sports restrictions on youth athletes, highlighting the largest problems, as well as how organizations can help youth athletes by preparing for and responding to these problems. Recent Findings Millions of children and adolescents worldwide participate in organized sports, which has significant physical and mental health benefits. In 2020, the COVID-19 pandemic triggered large-scale, public restrictions that forced the closure and cancelation of organized youth sports across the world. Sports cancelations not only removed these protective benefits, but also worsened the mental health of youth athletes who were no longer able to participate in their sports. Summary Youth athletes are even more vulnerable than adults to the negative mental health effects of sports restrictions. The unexpected loss of sports from COVID-19 restrictions disrupted these youths’ athletic identities and worsened youth athlete depression, anxiety, anger, sleep, and quality of life. Restrictions particularly affected certain high-risk subpopulations of youth athletes including females, high school upperclassmen, those from low socioeconomic backgrounds, and those from team sports. Sports organizations could limit the negative mental health impacts of future sports cancelations by implementing at-home training opportunities, remote check-ins with teammates, discussions about athletic identity with coaches and sports psychology professionals, and mindfulness skill-building.

Bonding and Attunement in Neuropsychiatric Disorders Laboratory, San Francisco, CA [email protected] Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA The authors have no conflicts of interest or financial disclosures to report.

Co-occurring posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) is common and particularly associated with elevation of hyperarousal compared to PTSD alone. Treatment options are limited. Oxytocin regulates physiological stress response. Intranasal oxytocin administration has demonstrated potential in reducing symptoms of both PTSD and AUD. This study addresses a gap in the literature by investigating effects of intranasal oxytocin on startle reactivity, an important potential marker of both PTSD and AUD symptomatology. This is a randomized, double-blind, placebo-controlled, within- and between-participant, crossover, dose-ranging study examining the effects of a single administration of oxytocin 20 IU versus 40 IU versus placebo on psychophysiological responses to a common laboratory fear-potentiated acoustic startle paradigm in participants with PTSD-AUD (n = 47) and controls (n = 37) under three different levels of threat. Contrary to our hypothesis, for the PTSD-AUD group, oxytocin 20 IU had no effect on startle reactivity, while oxytocin 40 IU increased measures of startle reactivity. Additionally, for PTSD-AUD only, ambiguous versus low threat was associated with an elevated skin conductance response. For controls only, oxytocin 20 IU versus placebo was associated with reduced startle reactivity.

INTRODUCTION:Mimicking movements of others makes both the imitating and imitated partners feel closer. Oxytocin may increase focus on others and has been shown to increase automatic imitation in healthy controls (HC). However, this has not been replicated, and oxytocin's effects on automatic imitation have not been demonstrated in clinical populations. This study attempts to replicate effects on HC and examine effects on people with comorbid posttraumatic stress disorder and alcohol use disorder (PTSD-AUD).METHODS:Fifty-four males with PTSD-AUD and 43 male HC received three intranasal treatment conditions (placebo, oxytocin 20 International Units (IU), and oxytocin 40 IU) in a randomized order, across three separate testing days, as part of a double-blind, crossover parent study. At 135 min post-administration, each performed the imitation-inhibition task, which quantifies automatic imitation as the congruency effect (CE). After exclusions, the final analyzed data set included 49 participants with PTSD-AUD and 38 HC.RESULTS:In HC, oxytocin 20 IU demonstrated a statistically significant increase in CE, and 40 IU showed a trend-level increase. In PTSD-AUD, oxytocin did not significantly increase CE. Post-hoc analysis showed the PTSD-AUD group had higher CE than HC on placebo visits.DISCUSSION:Our data suggest PTSD-AUD is associated with higher automatic imitation than HC in the absence of oxytocin administration. We successfully replicated findings that oxytocin increases automatic imitation in HC. This demonstrates an unconscious motor effect induced by oxytocin, likely relevant to more complex forms of imitative movements, which have the potential to improve social connection. We did not find a significant effect of oxytocin on automatic imitation in PTSD-AUD. Future research should examine imitation in both sexes, at peak oxytocin levels, and on increasingly complex forms of imitation.

BackgroundIndividuals with alcohol use disorder (AUD) are much more likely to meet criteria for posttraumatic stress disorder (PTSD) than the general population. Compared to AUD alone, those with comorbid AUD‐PTSD experience worse outcomes. Prior literature suggests that oxytocin, a hypothalamic neuropeptide, may be effective in the treatment of both AUD and PTSD when administered intranasally, although specific mechanisms remain elusive.MethodsForty‐seven male patients with comorbid AUD‐PTSD were administered intranasal oxytocin in a randomized, double‐blind, dose‐ranging (20 IU, 40 IU, and matched placebo), within‐participant design with study visits at least 1 week apart. A cue‐induced craving paradigm was conducted using each participant’s preferred alcoholic beverage versus a neutral water cue. Self‐reported alcohol craving and heart rate (HR) were recorded and analyzed using linear mixed‐effect models.ResultsWhile alcohol cues significantly induced self‐reported craving and increased HR compared to neutral water cues, neither dosage of oxytocin compared to placebo reduced self‐reported cue‐induced alcohol craving nor cue‐induced changes in HR in patients with PTSD‐AUD.ConclusionsThese preliminary findings suggest that oxytocin does not affect cue‐induced craving. Our results contribute to an ever‐growing field of research investigating the effects of intranasal oxytocin on the symptoms of substance use disorders and will help further refine methodology and streamline future inquiries in this area.

Existing treatments for individuals with comorbid PTSD and AUD are limited and inadequate. We aim to determine whether administration of intranasal oxytocin has beneficial anti-addiction, social, and hyperarousal-reducing effects in patients with PTSD/AUD. Differential effectiveness of high (40IU) versus low (20IU) dosages of oxytocin and predictors for individual responsiveness will be examined.

Bryostatin 1 has attracted considerable attention both as a cancer chemotherapeutic agent and for its unique activity. Although it functions, like phorbol esters, as a potent protein kinase C (PKC) activator, it paradoxically antagonizes many phorbol ester responses in cells. Because of its complex structure, little is known of its structure-function relations. Merle 23 is a synthetic derivative, differing from bryostatin 1 at only four positions. However, in U-937 human leukemia cells, Merle 23 behaves like a phorbol ester and not like bryostatin 1. Here, we characterize the behavior of Merle 23 in the human prostate cancer cell line LNCaP. In this system, bryostatin 1 and phorbol ester have contrasting activities, with the phorbol ester but not bryostatin 1 blocking cell proliferation or tumor necrosis factor alpha secretion, among other responses. We show that Merle 23 displays a highly complex pattern of activity in this system. Depending on the specific biological response or mechanistic change, it was bryostatin-like, phorbol ester-like, intermediate in its behavior, or more effective than either. The pattern of response, moreover, varied depending on the conditions. We conclude that the newly emerging bryostatin derivatives such as Merle 23 provide powerful tools to dissect subsets of bryostatin mechanism and response.